Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W3146464165', 'doi': None, 'title': 'Analyses of therapeutic effects using rludarabine and cytarabine on acute myeloid leukemia at different stages during treatment', 'display_name': 'Analyses of therapeutic effects using rludarabine and cytarabine on acute myeloid leukemia at different stages during treatment', 'publication_year': 2009, 'publication_date': '2009-01-01', 'ids': {'openalex': 'https://openalex.org/W3146464165', 'mag': '3146464165'}, 'language': 'zh-cn', 'primary_location': {'is_oa': False, 'landing_page_url': 'http://www.cqvip.com/QK/90333A/200906/30608600.html', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306542650', 'display_name': '中德临床肿瘤学杂志:英文版', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5100445657', 'display_name': 'Diandou Xu', 'orcid': 'https://orcid.org/0000-0002-0232-9091'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Xu', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5055227125', 'display_name': 'Xiaoli Chen', 'orcid': 'https://orcid.org/0000-0003-0207-2705'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Xiaoli', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5100358859', 'display_name': 'Shirong Liu', 'orcid': 'https://orcid.org/0000-0001-8719-4909'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Liu', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5034758302', 'display_name': 'Qjngfeng', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Qjngfeng', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5100735336', 'display_name': 'Mengxi Du', 'orcid': 'https://orcid.org/0000-0002-6406-7250'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Du', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5024811894', 'display_name': 'LingYun LingYun', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Lingyun', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5105474135', 'display_name': 'Ouyang', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Ouyang', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5081089826', 'display_name': 'Tomohiko Yamazaki', 'orcid': 'https://orcid.org/0000-0003-2136-8042'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Zhi', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5000119910', 'display_name': 'Lijun Lijun', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Lijun', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5046389053', 'display_name': 'Mengjing Hou', 'orcid': 'https://orcid.org/0000-0001-8588-8026'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Hou', 'raw_affiliation_strings': [], 'affiliations': []}], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 64}, 'biblio': {'volume': None, 'issue': '6', 'first_page': '349', 'last_page': '352'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10309', 'display_name': 'Acute Myeloid Leukemia', 'score': 0.999, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10309', 'display_name': 'Acute Myeloid Leukemia', 'score': 0.999, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11157', 'display_name': 'Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia', 'score': 0.9965, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11215', 'display_name': 'Efficacy and Resistance in CML Treatment', 'score': 0.9872, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/acute-myeloid-leukemia', 'display_name': 'Acute Myeloid Leukemia', 'score': 0.479228}], 'concepts': [{'id': 'https://openalex.org/C2778041864', 'wikidata': 'https://www.wikidata.org/wiki/Q180983', 'display_name': 'Cytarabine', 'level': 3, 'score': 0.91694033}, {'id': 'https://openalex.org/C2778729363', 'wikidata': 'https://www.wikidata.org/wiki/Q11688946', 'display_name': 'Myeloid leukemia', 'level': 2, 'score': 0.85868585}, {'id': 'https://openalex.org/C2779263901', 'wikidata': 'https://www.wikidata.org/wiki/Q185916', 'display_name': 'Fludarabine', 'level': 4, 'score': 0.747563}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.6091993}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.57642627}, {'id': 'https://openalex.org/C2779282312', 'wikidata': 'https://www.wikidata.org/wiki/Q1956561', 'display_name': 'Myeloid', 'level': 2, 'score': 0.5028586}, {'id': 'https://openalex.org/C2778461978', 'wikidata': 'https://www.wikidata.org/wiki/Q29496', 'display_name': 'Leukemia', 'level': 2, 'score': 0.4839118}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.35870683}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.35512644}, {'id': 'https://openalex.org/C2776755627', 'wikidata': 'https://www.wikidata.org/wiki/Q408524', 'display_name': 'Cyclophosphamide', 'level': 3, 'score': 0.18516314}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'http://www.cqvip.com/QK/90333A/200906/30608600.html', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306542650', 'display_name': '中德临床肿瘤学杂志:英文版', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3209060277', 'https://openalex.org/W3150498179', 'https://openalex.org/W3149136454', 'https://openalex.org/W3145892807', 'https://openalex.org/W3142402858', 'https://openalex.org/W3032814887', 'https://openalex.org/W3032468963', 'https://openalex.org/W3032341943', 'https://openalex.org/W3032212330', 'https://openalex.org/W3029082501', 'https://openalex.org/W2996435505', 'https://openalex.org/W2944522084', 'https://openalex.org/W2906062718', 'https://openalex.org/W2897968503', 'https://openalex.org/W2792515217', 'https://openalex.org/W2762458860', 'https://openalex.org/W2171295471', 'https://openalex.org/W2090384198', 'https://openalex.org/W1993422021', 'https://openalex.org/W1578009681'], 'abstract_inverted_index': {'目的将在治疗期间在不同阶段在尖锐': [0], 'myeloid': [1], '白血病(AML': [2], ')': [3, 9, 23, 29, 35, 41, 55, 64, 67, 70, 73, 85, 91], '上评估': [4], 'fludarabine': [5], '和': [6, 45, 60], 'cytarabine': [7], '(FA': [8], '政体的治疗学的效果。有': [10], 'AML': [11, 48, 95], '的': [12], '185': [13], '个病人全部的方法': [14], 'A': [15], '基于以前的治疗的结果被划分成': [16], '4': [17, 37, 46, 51, 61], '个组。在组': [18], '1': [19, 78], '的病人没在正式就职化疗的第一堂功课以后有宽恕(n': [20], '=': [21, 27, 33, 39, 83, 89], '55': [22], '。在组': [24, 30, 36], '2': [25], '的病人没在正式就职化疗的不亚于二堂功课以后有宽恕(n': [26], '41': [28], '3': [31, 44, 59, 76], '的病人有早恶化(n': [32], '40': [34], '的病人有迟了的恶化(n': [38], '49': [40], '。在组的病人有恶化的': [42], '2,': [43, 58], '有的倔强的': [47], '或': [49], 'AML。我们在每这': [50], '个组估计了': [52], 'FA': [53, 93], '联合化疗的功效和毒性。完全的宽恕(CR': [54], '组评估的结果': [56], '1,': [57], '是': [62], '74.5%(41/55': [63], ',': [65, 68, 80], '45.9%(19/41': [66], '17.5%(7/40': [69], '并且': [71], '38.8%(19/49': [72], '分别地。CR': [74], '率在比在另外的': [75], '个组的组': [77], '是更高的(34.6%': [79], '45/130': [81], ')(P': [82], '0.000': [84], '。重要关联在': [86], 'CR': [87], '率和化学疗法的功课的数字之间被发现(P': [88], '0.023': [90], '。主要不利反应包括了骨头髓抑制和继发感染。结论': [92], '政体是为有': [94], '的病人的一种好选择,特别失败了到的那些在正式就职化疗的第一棵菜以后完成': [96], 'CR。': [97]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3146464165', 'counts_by_year': [], 'updated_date': '2024-08-21T17:34:03.323613', 'created_date': '2021-04-13'}